9 completed. 6 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
Follow ARRY-334543: new trials by email Literature Review of ARRY-334543 trials Research Report on ARRY-334543
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) Varlitinib, mFOLFOX6, Placebo - Gastric Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 52 | 2017-08-31 | 2022-02-15 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy Varlitinib - Cholangiocarcinoma | Phase 2 | Completed | ASLAN Pharmaceuticals | 32 | 2015-11-16 | 2018-05-29 |
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine ASLAN001, cisplatin + capecitabine, cisplatin + 5-fluorouracil (or+ Leucovorin) - Solid Tumor | Phase 1 | Completed | ASLAN Pharmaceuticals | 31 | 2014-08-05 | 2018-10-25 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2009-03-01 | 2012-10-04 |
| A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Docetaxel, mitotic inhibitor; intravenous, Prophylactic growth factors; subcutaneous - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 27 | 2009-01-01 | 2020-10-06 |
| A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Capecitabine, 5-fluorouracil prodrug; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 29 | 2008-06-01 | 2020-10-06 |
| A Study of ARRY-334543 in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 31 | 2008-02-01 | 2020-10-08 |
| A Study of ARRY-334543 in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 96 | 2006-01-01 | 2020-10-14 |
Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
ASLAN Pharmaceuticals (4) · Array Biopharma, now a wholly owned subsidiary of Pfizer (4) · Array BioPharma (1)
United States (5) · Taiwan (4) · Canada (3) · Hong Kong (3) · Singapore (3) · South Korea (3) · Australia (1) · China (1) · Estonia (1) · Hungary (1) · Japan (1) · Lithuania (1) · Malaysia (1) · Poland (1) · Spain (1)